vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与FIRST US BANCSHARES, INC.（FUSB）财务数据对比。点击上方公司名可切换其他公司
CHAMPIONS ONCOLOGY, INC.的季度营收约是FIRST US BANCSHARES, INC.的1.4倍（$15.0M vs $10.4M），FIRST US BANCSHARES, INC.净利率更高（20.4% vs 1.8%，领先18.7%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs 7.1%），FIRST US BANCSHARES, INC.自由现金流更多（$9.1M vs $-2.0M），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs 2.6%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
第一美国银行控股公司是一家银行控股企业，核心子公司第一公民银行在美国23个州经营着超过500家网点，另一家子公司硅谷银行则在15个州设有39个办事处，是美国规模较大的银行机构之一，总部位于北卡罗来纳州罗利。
CSBR vs FUSB — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $10.4M |
| 净利润 | $268.0K | $2.1M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 1.2% | 28.1% |
| 净利率 | 1.8% | 20.4% |
| 营收同比 | 11.5% | 7.1% |
| 净利润同比 | -63.2% | 24.2% |
| 每股收益（稀释后） | $0.02 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $15.0M | $10.4M | ||
| Q3 25 | $14.0M | $10.5M | ||
| Q2 25 | $12.4M | $10.3M | ||
| Q1 25 | $17.0M | $9.8M | ||
| Q4 24 | $13.5M | $9.7M | ||
| Q3 24 | $14.1M | $10.1M | ||
| Q2 24 | $14.0M | $10.0M | ||
| Q1 24 | $12.0M | $9.9M |
| Q4 25 | $268.0K | $2.1M | ||
| Q3 25 | $-436.0K | $1.9M | ||
| Q2 25 | $-1.8M | $155.0K | ||
| Q1 25 | $4.5M | $1.8M | ||
| Q4 24 | $728.0K | $1.7M | ||
| Q3 24 | $1.3M | $2.2M | ||
| Q2 24 | $-109.0K | $2.1M | ||
| Q1 24 | $-2.5M | $2.1M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 28.1% | ||
| Q3 25 | -3.8% | 23.9% | ||
| Q2 25 | -16.2% | 1.6% | ||
| Q1 25 | 26.4% | 23.8% | ||
| Q4 24 | 5.4% | 23.8% | ||
| Q3 24 | 9.5% | 29.2% | ||
| Q2 24 | -1.9% | 27.4% | ||
| Q1 24 | -21.4% | 27.8% |
| Q4 25 | 1.8% | 20.4% | ||
| Q3 25 | -3.1% | 18.4% | ||
| Q2 25 | -14.9% | 1.5% | ||
| Q1 25 | 26.4% | 18.1% | ||
| Q4 24 | 5.4% | 17.6% | ||
| Q3 24 | 9.3% | 22.0% | ||
| Q2 24 | -0.8% | 21.2% | ||
| Q1 24 | -21.1% | 21.3% |
| Q4 25 | $0.02 | $0.36 | ||
| Q3 25 | $-0.03 | $0.32 | ||
| Q2 25 | $-0.12 | $0.03 | ||
| Q1 25 | $0.31 | $0.29 | ||
| Q4 24 | $0.05 | $0.29 | ||
| Q3 24 | $0.09 | $0.36 | ||
| Q2 24 | $-0.01 | $0.34 | ||
| Q1 24 | $-0.19 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $73.5M |
| 总债务越低越好 | — | $10.9M |
| 股东权益账面价值 | $4.2M | $105.6M |
| 总资产 | $30.2M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.10× |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $73.5M | ||
| Q3 25 | $10.3M | $54.7M | ||
| Q2 25 | $9.8M | $54.0M | ||
| Q1 25 | $3.2M | $56.0M | ||
| Q4 24 | $2.8M | $47.2M | ||
| Q3 24 | $2.9M | $82.3M | ||
| Q2 24 | $2.6M | $58.2M | ||
| Q1 24 | $4.5M | $60.2M |
| Q4 25 | — | $10.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $10.9M | ||
| Q1 25 | — | $10.9M | ||
| Q4 24 | — | $10.9M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $10.8M | ||
| Q1 24 | — | $10.8M |
| Q4 25 | $4.2M | $105.6M | ||
| Q3 25 | $3.5M | $104.2M | ||
| Q2 25 | $3.8M | $101.9M | ||
| Q1 25 | $5.5M | $101.2M | ||
| Q4 24 | $681.0K | $98.6M | ||
| Q3 24 | $-332.0K | $98.5M | ||
| Q2 24 | $-1.9M | $93.8M | ||
| Q1 24 | $-2.1M | $92.3M |
| Q4 25 | $30.2M | $1.2B | ||
| Q3 25 | $30.5M | $1.1B | ||
| Q2 25 | $32.3M | $1.1B | ||
| Q1 25 | $30.6M | $1.1B | ||
| Q4 24 | $25.2M | $1.1B | ||
| Q3 24 | $24.9M | $1.1B | ||
| Q2 24 | $26.1M | $1.1B | ||
| Q1 24 | $26.8M | $1.1B |
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $12.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $9.1M |
| 自由现金流率自由现金流/营收 | -13.1% | 87.2% |
| 资本支出强度资本支出/营收 | 1.6% | 31.1% |
| 现金转化率经营现金流/净利润 | -6.47× | 5.79× |
| 过去12个月自由现金流最近4个季度 | $5.6M | $16.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-1.7M | $12.3M | ||
| Q3 25 | $600.0K | $4.2M | ||
| Q2 25 | $6.9M | $3.9M | ||
| Q1 25 | $490.0K | $1.8M | ||
| Q4 24 | $-283.0K | $7.8M | ||
| Q3 24 | $311.0K | $1.9M | ||
| Q2 24 | $-1.8M | $2.5M | ||
| Q1 24 | $-919.0K | $825.0K |
| Q4 25 | $-2.0M | $9.1M | ||
| Q3 25 | $554.0K | $3.6M | ||
| Q2 25 | $6.6M | $1.6M | ||
| Q1 25 | $448.0K | $1.7M | ||
| Q4 24 | $-377.0K | $5.7M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | $-1.8M | $2.3M | ||
| Q1 24 | $-1.0M | $-142.0K |
| Q4 25 | -13.1% | 87.2% | ||
| Q3 25 | 4.0% | 34.2% | ||
| Q2 25 | 53.5% | 16.0% | ||
| Q1 25 | 2.6% | 17.2% | ||
| Q4 24 | -2.8% | 58.2% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | -13.0% | 23.5% | ||
| Q1 24 | -8.4% | -1.4% |
| Q4 25 | 1.6% | 31.1% | ||
| Q3 25 | 0.3% | 5.9% | ||
| Q2 25 | 2.0% | 21.8% | ||
| Q1 25 | 0.2% | 0.7% | ||
| Q4 24 | 0.7% | 21.6% | ||
| Q3 24 | 0.0% | 6.6% | ||
| Q2 24 | 0.0% | 2.0% | ||
| Q1 24 | 0.8% | 9.8% |
| Q4 25 | -6.47× | 5.79× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | — | 25.16× | ||
| Q1 25 | 0.11× | 0.99× | ||
| Q4 24 | -0.39× | 4.53× | ||
| Q3 24 | 0.24× | 0.87× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 0.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FUSB
暂无分部数据
